Natural History of Advanced Primary Hyperoxaluria Type 1: A Retrospective Study
John C. Lieske(Mayo Clinic), John M. Gansner(Brigham and Women's Hospital), Hadas Shasha‐Lavsky(Université Claude Bernard Lyon 1), Daniel G. Fuster(University Hospital of Bern), Anne‐Laure Sellier‐Leclerc(Hôpital Femme Mère Enfant), Arnaud Devresse(Cliniques Universitaires Saint-Luc), Farshad Kajbaf(Alnylam Pharmaceuticals (United States)), Yaacov Frishberg(Shaare Zedek Medical Center), Sander F. Garrelfs(Emma Kinderziekenhuis), Dawn S. Milliner(Mayo Clinic), Ruth Cytter-Kuint(Shaare Zedek Medical Center), Daniella Magen(Université Claude Bernard Lyon 1), Sevcan A. Bakkaloğlu, Jaap W. Groothoff(University of Amsterdam), Sandrine Lemoine(Université Claude Bernard Lyon 1), W. J. Du(Alnylam Pharmaceuticals (United States))
Cited by 2
Related Papers
Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1
|New England Journal of Medicine|2021|505
COQ6 mutations in human patients produce nephrotic syndrome with sensorineural deafness
|Journal of Clinical Investigation|2011|402
The primary hyperoxalurias
|Kidney International|2009|373
Design of the Nephrotic Syndrome Study Network (NEPTUNE) to evaluate primary glomerular nephropathy by a multidisciplinary approach
|Kidney International|2013|350
Primary hyperoxaluria Type 1: indications for screening and guidance for diagnosis and treatment
|Nephrology Dialysis Transplantation|2012|335